# Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora

> **NCT04366089** · PHASE2 · UNKNOWN · sponsor: **Roberto Poscia MD, PhD** · enrollment: 152 (estimated)

## Conditions studied

- COVID
- SARS-CoV 2
- Pneumonia, Viral
- Coronavirus Infection

## Interventions

- **OTHER:** Oxygen-ozone therapy, probiotic supplementation and Standard of care
- **DIETARY_SUPPLEMENT:** SivoMixx (200 billion)
- **DRUG:** Azithromycin
- **DRUG:** hydroxychloroquine

## Key facts

- **NCT ID:** NCT04366089
- **Lead sponsor:** Roberto Poscia MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-26
- **Primary completion:** 2020-10-30
- **Final completion:** 2020-12-31
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2020-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04366089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04366089, "Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04366089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*